Advanced Prostate Cancer Clinical Trial
Official title:
Cabazitaxel With BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer Following Treatment With Docetaxel: Phase II Study With Safety Lead-in Cohort
Although there have been advances in the treatment of patients with metastatic castrate-resistant prostate cancer (mCRPC), all patients eventually develop resistance to available therapy. Docetaxel is the accepted first-line agent followed by cabazitaxel in the post-docetaxel phase. In this study the investigators propose to evaluate BKM120, a PI3K inhibitor, with cabazitaxel in the treatment of patients with advanced prostate cancer.
This study will be conducted in two parts. In a lead-in cohort, the feasibility and safety
of administering BKM120 with a standard dose of cabazitaxel will be assessed. If safety is
confirmed, a subsequent Phase II portion will assess the activity of the combination in
patients with mCRPC previously treated with docetaxel. The treatment will consist of 3-week
(21-day) cycles.
The ultimate purpose of this study will be to determine progression-free survival, response
rate, disease control rate and overall survival of patients treated with the combination
regimen and compare outcomes to historical results with single-agent cabazitaxel.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06006104 -
Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03936218 -
Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer
|
Phase 3 | |
| Completed |
NCT02234089 -
Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.
|
||
| Completed |
NCT01078545 -
Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)
|
N/A | |
| Active, not recruiting |
NCT03511196 -
Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer
|
Early Phase 1 | |
| Recruiting |
NCT05942001 -
Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
Phase 1 | |
| Active, not recruiting |
NCT04117594 -
Whole Body Magnetic Resonance Imaging Study
|
||
| Not yet recruiting |
NCT06369246 -
PRORAD-5 PROstate RADiation in 5 Fractions: Phase Ib Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer
|
Phase 2 | |
| Completed |
NCT01383863 -
A Long-term Observational Study Cohort in Patients With Advanced Prostate Cancer
|
||
| Completed |
NCT03651271 -
Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT05590793 -
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
|
Phase 3 | |
| Recruiting |
NCT06095089 -
A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT02362620 -
PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.
|
||
| Active, not recruiting |
NCT02787837 -
PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate.
|
||
| Recruiting |
NCT05800665 -
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
|
Phase 1 | |
| Recruiting |
NCT03938649 -
SRAM study_Postate Cancer
|
Phase 2 | |
| Completed |
NCT00871585 -
Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide
|
N/A | |
| Active, not recruiting |
NCT02922218 -
PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in mCRPC Patients Treated With Enzalutamide.
|
||
| Not yet recruiting |
NCT06335914 -
Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer
|
N/A | |
| Terminated |
NCT03577028 -
Study of HPN424 in Patients With Advanced Prostate Cancer
|
Phase 1/Phase 2 |